Background: Obesity is a major risk factor for several chronic diseases. The BioEnterics® Intragastric Balloon (BIB®) is used worldwide as a short-term (6 months) treatment in morbid obese patients. However, removal of BIB® past 6 months is a common occurrence in clinical practice often as a result of patient factors. The aim of the present Italian multicentre cohort study was to evaluate the safety and efficacy of the BIB® left in situ for more than 6 months. Materials and methods: A total of eight Italian centres participated in the study. Participating centres received a standardised questionnaire designed to capture safety and efficacy data. Weight loss data, as well as date, and reason for removal of the BIB® after 6 months were recorded. Adverse events, including mortality and complications, operators’ subjective technical notes and findings, and difficulties during removal procedure were also collected. Results: Six hundred and eleven patients were included. In the majority of cases, patient extended BIB® treatment due to satisfactory weight loss (44 %). At 6 months, all patients achieved a BMI statistically lower than the initial BMI (p ® use up to 14 months safely maintains weight loss and satiety with greater results than that up to 6 months, without complications.
|Number of pages||5|
|Journal||Surgical Endoscopy and Other Interventional Techniques|
|Publication status||Published - Aug 25 2015|
- Intragastric balloon
- Obesity management
- Weight loss
ASJC Scopus subject areas